← Leaderboards
Carlos A Pardo-Villamizar
Johns Hopkins University
$6,851,889
Attributed
$7,144,608
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,144,608 · 7
By mechanism
R01$5,280,351 · 3
R21$944,207 · 2
K08$870,050 · 1
R13$50,000 · 1
Top collaborators
- Monique F. Stins2 shared
- Nisha Aggarwal Gilotra1 shared
- Michelle Sharp1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Peter P Zandi$14,805,431
- Heather E Volk$25,829,133
- Stephen R Cole$4,865,193
- Chetan Bettegowda$9,213,403
- Valina L. Dawson$28,150,357
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPathogenesisNeurologicMolecularResponseInflammatoryMicrobialSamplingImmuneAffectDiagnosisBiologicalPatient RecruitmentsGenomicsAreaIncidenceImmune ResponseEncephalitisImmunologicsPathogenMyelitisAntigensNeuroinflammationAntibodies
Grant awards (22)
Neurosarcoidosis: Clinical Phenotype, Biomarkers and Immunopathogensis$659,661
R01 · FY2025 · NS · contact PI
Neurosarcoidosis: Clinical Phenotype, Biomarkers and Immunopathogensis$643,385
R01 · FY2024 · NS · contact PI
Americas Association of Sarcoidosis and Other Granulomatous Disorders 2024: The Art of Working Together for Progress$50,000
R13 · FY2024 · HL
Neurosarcoidosis: Clinical Phenotype, Biomarkers and Immunopathogensis$661,080
R01 · FY2023 · NS · contact PI
Emerging Neuroviruses and Neurological Inflammatory Diseases$324,682
R01 · FY2023 · NS · contact PI
Neurosarcoidosis: Clinical Phenotype, Biomarkers and Immunopathogensis$676,226
R01 · FY2022 · NS · contact PI
Emerging Neuroviruses and Neurological Inflammatory Diseases$324,682
R01 · FY2022 · NS · contact PI
Brain Vascular Heterogeneity$230,948
R21 · FY2022 · NS · contact PI
Emerging Neuroviruses and Neurological Inflammatory Diseases$324,682
R01 · FY2021 · NS · contact PI
Brain Vascular Heterogeneity$287,823
R21 · FY2021 · NS · contact PI
Emerging Neuroviruses and Neurological Inflammatory Diseases$324,682
R01 · FY2020 · NS · contact PI
Emerging Neuroviruses and Neurological Inflammatory Diseases$373,619
R01 · FY2019 · NS · contact PI
In-vitro brain organotypic model of Progressive Multifocal Leukoencephalopathy$195,413
R21 · FY2013 · NS · contact PI
Role of CNS Opportunistic Infections in Subsequent Development of HIV Encephaliti$321,457
R01 · FY2012 · NS · contact PI
In-vitro brain organotypic model of Progressive Multifocal Leukoencephalopathy$230,023
R21 · FY2012 · NS · contact PI
Role of CNS Opportunistic Infections in Subsequent Development of HIV Encephaliti$321,457
R01 · FY2011 · NS · contact PI
Role of CNS Opportunistic Infections in Subsequent Development of HIV Encephaliti$324,738
R01 · FY2010 · NS · contact PI
HIV infection and drugs of abuse in neuroglial function$183,276
K08 · FY2007 · DA · contact PI
HIV infection and drugs of abuse in neuroglial function$183,276
K08 · FY2006 · DA · contact PI
HIV infection and drugs of abuse in neuroglial function$172,005
K08 · FY2005 · DA
HIV infection and drugs of abuse in neuroglial function$167,778
K08 · FY2004 · DA
HIV infection and drugs of abuse in neuroglial function$163,715
K08 · FY2003 · DA